HomeCompareCXDC vs PFE

CXDC vs PFE: Dividend Comparison 2026

CXDC yields 83333.33% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CXDC wins by $7.827354174349132e+25M in total portfolio value
10 years
CXDC
CXDC
● Live price
83333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.827354174349132e+25M
Annual income
$78,089,205,798,879,010,000,000,000,000,000.00
Full CXDC calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CXDC vs PFE

📍 CXDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCXDCPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CXDC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CXDC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CXDC
Annual income on $10K today (after 15% tax)
$7,083,333.33/yr
After 10yr DRIP, annual income (after tax)
$66,375,824,929,047,160,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CXDC beats the other by $66,375,824,929,047,160,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CXDC + PFE for your $10,000?

CXDC: 50%PFE: 50%
100% PFE50/50100% CXDC
Portfolio after 10yr
$3.913677087174566e+25M
Annual income
$39,044,602,899,439,506,000,000,000,000,000.00/yr
Blended yield
99.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CXDC
Analyst Ratings
1
Buy
Consensus: Buy
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CXDC buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCXDCPFE
Forward yield83333.33%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$7.827354174349132e+25M$49.6K
Annual income after 10y$78,089,205,798,879,010,000,000,000,000,000.00$26,258.71
Total dividends collected$7.826145752529585e+25M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: CXDC vs PFE ($10,000, DRIP)

YearCXDC PortfolioCXDC Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$8,344,033$8,333,333.33$9,153$693.39+$8.33MCXDC
2$6,507,396,444$6,498,468,328.14$8,593$849.25+$6507.39MCXDC
3$4,743,472,976,069$4,736,510,061,874.32$8,336$1,066.78+$4743472.97MCXDC
4$3,231,814,615,629,740$3,226,739,099,545,346.00$8,437$1,384.80+$3231814615.62MCXDC
5$2,058,071,288,713,008,000$2,054,613,247,074,284,500.00$9,013$1,875.40+$2058071288713.00MCXDC
6$1,225,015,790,649,354,000,000$1,222,813,654,370,431,000,000.00$10,306$2,680.72+$1225015790649354.00MCXDC
7$681,543,888,689,022,700,000,000$680,233,121,793,028,000,000,000.00$12,820$4,101.38+$681543888689022720.00MCXDC
8$354,421,985,930,988,300,000,000,000$353,692,733,970,091,100,000,000,000.00$17,673$6,826.70+$354421985930988290048.00MCXDC
9$172,276,583,749,827,040,000,000,000,000$171,897,352,224,880,900,000,000,000,000.00$27,543$12,591.86+$1.7227658374982704e+23MCXDC
10$78,273,541,743,491,320,000,000,000,000,000$78,089,205,798,879,010,000,000,000,000,000.00$49,560$26,258.71+$7.827354174349132e+25MCXDC

CXDC vs PFE: Complete Analysis 2026

CXDCStock

China XD Plastics Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of modified plastics primarily for automotive applications in the People's Republic of China, and Dubai, the United Arab Emirates. Its modified plastics are used to fabricate various auto components, including exteriors consisting of automobile bumpers, rearview and sideview mirrors, and license plate parts; interiors, such as door panels, steering wheels, dashboards, glove compartments, and safety belt components; and functional components comprising air conditioner casings, heating and ventilation casings, engine covers, and air ducts. The company also offers engineered plastics and environment-friendly plastics for use in oilfield equipment, mining equipment, vessel propulsion systems, and power station equipment; and polymer composite materials. Its products are also used in high-speed railways, airplanes, ships, and electronic appliances. The company sells its products through distributors, as well as directly to end customers. China XD Plastics Company Limited was founded in 1985 and is headquartered in Harbin, the People's Republic of China.

Full CXDC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CXDC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CXDC vs SCHDCXDC vs JEPICXDC vs OCXDC vs KOCXDC vs MAINCXDC vs JNJCXDC vs MRKCXDC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.